Seyyedeh Mina Hejazian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seyyedeh Mina Hejazian has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Mohammadreza Ardalan
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
23 shared publications - Sepideh Zununi Vahed
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
21 shared publications - Farahnoosh Farnood
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
7 shared publications - Bahram Niknafs
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
5 shared publications - Elham Ahmadian
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
5 shared publications - Mehdi Haghi
Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
4 shared publications
Latest Publications
- 17 October 2025
- Published by Elsevier in International Dairy Journal
- Vol. 172
Milk-derived Extracellular Vesicles: Tiny Messengers with Big Impacts on Human Health
- 17 October 2025
- Published by Elsevier in International Dairy Journal
- Vol. 172
Milk-derived Extracellular Vesicles: Tiny Messengers with Big Impacts on Human Health
- Open Access
- 6 September 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15 (1) , 30989
microRNAs shuttled by mesenchymal stromal cell-derived exosomes in coronary artery disease: A systematic review of preclinical studies
Introduction: Coronary artery disease (CAD) is a life-threatening cardiac condition with high morbidity and mortality worldwide. This systematic review article highlighted the therapeutic roles of mesenchymal stromal cells (MSCs)-derived exosomal microRNAs (exo-miRs) in preclinical models of CAD. Methods: A comprehensive search was conducted on PubMed, Web of Science, Scopus, and Google Scholar to identify relevant publications until 04 Apr 2025. The literature review focuses on the origin of MSCs, the technique employed for exosome extraction and identification, the route and frequency of exosomal administration, the mechanisms through which exo-miRs regulate paracrine activity, and their impact on cardiac outcome. Results: After meticulous evaluation, fifty-six studies were deemed eligible for inclusion in this systematic review. Bone marrow-derived MSCs were the most commonly utilized cell type in the preclinical studies. The majority of studies employed the ultracentrifugation method for exosome isolation from MSCs. The administration of exosomes was primarily achieved through a single intramyocardial injection, utilizing a wide range of exosome concentrations (ranging from 0.02-400 μg/μL). Conclusion: The included studies predominantly have reported the anti-inflammatory, anti-apoptotic, angiogenic, antifibrotic, and reparative effects of MSC-exo-miRs, especially under hypoxic conditions. These findings support the capacity of MSC-exo-miRs to regulate the immune system and facilitate cardiac recovery following an injury.
- 6 September 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15 (1) , 30989
Open AccessmicroRNAs shuttled by mesenchymal stromal cell-derived exosomes in coronary artery disease: A systematic review of preclinical studies
Introduction: Coronary artery disease (CAD) is a life-threatening cardiac condition with high morbidity and mortality worldwide. This systematic review article highlighted the therapeutic roles of mesenchymal stromal cells (MSCs)-derived exosomal microRNAs (exo-miRs) in preclinical models of CAD. Methods: A comprehensive search was conducted on PubMed, Web of Science, Scopus, and Google Scholar to identify relevant publications until 04 Apr 2025. The literature review focuses on the origin of MSCs, the technique employed for exosome extraction and identification, the route and frequency of exosomal administration, the mechanisms through which exo-miRs regulate paracrine activity, and their impact on cardiac outcome. Results: After meticulous evaluation, fifty-six studies were deemed eligible for inclusion in this systematic review. Bone marrow-derived MSCs were the most commonly utilized cell type in the preclinical studies. The majority of studies employed the ultracentrifugation method for exosome isolation from MSCs. The administration of exosomes was primarily achieved through a single intramyocardial injection, utilizing a wide range of exosome concentrations (ranging from 0.02-400 μg/μL). Conclusion: The included studies predominantly have reported the anti-inflammatory, anti-apoptotic, angiogenic, antifibrotic, and reparative effects of MSC-exo-miRs, especially under hypoxic conditions. These findings support the capacity of MSC-exo-miRs to regulate the immune system and facilitate cardiac recovery following an injury.
- Open Access
- 10 June 2025
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Investigating cognitive function in patients with end-stage kidney disease under hemodialysis or peritoneal dialysis; a cross-sectional study
Introduction: Studies have shown that patients with chronic kidney failure and patients under dialysis have a significantly augmented risk of developing cognitive damage compared to the general population. Objectives: The purpose of this study was to explore cognitive function in people with end-stage kidney disease (ESKD) under hemodialysis or peritoneal dialysis who were referred to the dialysis center of Imam Reza Hospital in 2024. Materials and Methods: This cross-sectional study included 200 patients (100 patients under hemodialysis and 100 patients under peritoneal dialysis). Through a standardized MMSE (mini-mental state examination) questionnaire, the cognitive function of the patients was examined and compared between the two groups. Results: In this study, all variables of cognitive function including awareness of time (P<0.001), awareness of place (P<0.001), recall (P<0.001), attention and calculation (P<0.001), drawing (P=0.003), and MMSE total score (P<0.001) were significantly higher in patients under peritoneal dialysis in compared to patients under hemodialysis. Conclusion: Cognitive function appears to be significantly better in patients with ESKD under peritoneal dialysis than in those under hemodialysis. Given the high prevalence of cognitive impairment and its association with adverse outcomes, routine cognitive screening and individualized management strategies should be considered, regardless of dialysis modality.
- 10 June 2025
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Open AccessInvestigating cognitive function in patients with end-stage kidney disease under hemodialysis or peritoneal dialysis; a cross-sectional study
Introduction: Studies have shown that patients with chronic kidney failure and patients under dialysis have a significantly augmented risk of developing cognitive damage compared to the general population. Objectives: The purpose of this study was to explore cognitive function in people with end-stage kidney disease (ESKD) under hemodialysis or peritoneal dialysis who were referred to the dialysis center of Imam Reza Hospital in 2024. Materials and Methods: This cross-sectional study included 200 patients (100 patients under hemodialysis and 100 patients under peritoneal dialysis). Through a standardized MMSE (mini-mental state examination) questionnaire, the cognitive function of the patients was examined and compared between the two groups. Results: In this study, all variables of cognitive function including awareness of time (P<0.001), awareness of place (P<0.001), recall (P<0.001), attention and calculation (P<0.001), drawing (P=0.003), and MMSE total score (P<0.001) were significantly higher in patients under peritoneal dialysis in compared to patients under hemodialysis. Conclusion: Cognitive function appears to be significantly better in patients with ESKD under peritoneal dialysis than in those under hemodialysis. Given the high prevalence of cognitive impairment and its association with adverse outcomes, routine cognitive screening and individualized management strategies should be considered, regardless of dialysis modality.
- Open Access
- 23 December 2024
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 16 (4) , 243-248
The protective effect of Edaravone against acute renocardiac syndrome in a kidney ischemia-reperfusion model
Introduction: Acute kidney injury (AKI) is a common clinical occurrence causing high mortality and morbidity. In acute renocardiac syndrome, AKI leads to acute cardiac injury or/and dysfunction. This study aimed to investigate the antioxidative effects of Edaravone on cardiac tissues following the induction of renal ischemia-reperfusion injury (IRI) in rats. Methods: Twenty-four male Wistar rats were randomly divided into four groups: IR+Edaravone, Edaravone, IR, and Sham groups (six rats per group). Non-traumatic clamps were used to stop the artery and vein blood flow of the left kidney in rats of the IR groups for 45 minutes. Thirty minutes before ischemia induction, Edaravone (3 mg/kg) was injected intraperitoneally in the IR+Edaravone group. Cardiac samples were subjected to biochemical analyses. Results: The Results showed a significant increase in the enzymatic activity of glutathione peroxidase (P=0.01), catalase (P=0.03), and superoxide dismutase (P=0.02), and the levels of glutathione (P=0.012), and total antioxidant capacity (P<0.001) in the IR+Edaravone group in comparison to the IR group. Moreover, the total antioxidant capacity of the heart was increased in the Edaravone group compared to the control and IR groups (P<0.001), indicating the safety of the drug. Conclusion: The results can reveal important insights into the protective effects of Edaravone against acute renocardiac syndrome.
- 23 December 2024
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 16 (4) , 243-248
Open AccessThe protective effect of Edaravone against acute renocardiac syndrome in a kidney ischemia-reperfusion model
Introduction: Acute kidney injury (AKI) is a common clinical occurrence causing high mortality and morbidity. In acute renocardiac syndrome, AKI leads to acute cardiac injury or/and dysfunction. This study aimed to investigate the antioxidative effects of Edaravone on cardiac tissues following the induction of renal ischemia-reperfusion injury (IRI) in rats. Methods: Twenty-four male Wistar rats were randomly divided into four groups: IR+Edaravone, Edaravone, IR, and Sham groups (six rats per group). Non-traumatic clamps were used to stop the artery and vein blood flow of the left kidney in rats of the IR groups for 45 minutes. Thirty minutes before ischemia induction, Edaravone (3 mg/kg) was injected intraperitoneally in the IR+Edaravone group. Cardiac samples were subjected to biochemical analyses. Results: The Results showed a significant increase in the enzymatic activity of glutathione peroxidase (P=0.01), catalase (P=0.03), and superoxide dismutase (P=0.02), and the levels of glutathione (P=0.012), and total antioxidant capacity (P<0.001) in the IR+Edaravone group in comparison to the IR group. Moreover, the total antioxidant capacity of the heart was increased in the Edaravone group compared to the control and IR groups (P<0.001), indicating the safety of the drug. Conclusion: The results can reveal important insights into the protective effects of Edaravone against acute renocardiac syndrome.
- Open Access
- 30 November 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 14, e38389
The aquaporin 5 promoter polymorphism and cytomegalovirus infection in kidney transplant recipients
Introduction: Cytomegalovirus (CMV) infection is a significant complication in kidney transplant recipients, impacting graft function and overall patient outcomes. Aquaporin 5 (AQP5) is a transmembrane channel that regulates renal function and impacts important mechanisms of immune cell migration and inflammation. Objectives: This research aimed to evaluate the impact of AQP5 polymorphism (-1364A/C) on the risk of CMV infection in kidney transplant recipients. Patients and Methods: One-hundred kidney transplant recipients were included in this study, divided into two groups; CMV+-positive (n=50) and CMV– -negative (n=50) patients. Additionally, a control group of 50 healthy individuals was included. The frequency of the AQP5 (-1364A/C) gene polymorphism was determined using the ARMS-PCR technique. Results: About 26% and 16% of patients in the CMV+ and CMV- groups experienced acute rejection after renal transplantation, respectively (P=0.220). The CC genotype of AQP5 (-1364A/C) polymorphism was present in 8% (n=4) of CMV+ and 4% (n=2) of CMV- recipients (4%); however, it was not observed in the control group (P=0.354). Conclusion: The results revealed that carrying at least one C-allele of the AQP5 1364A/C polymorphism (AC or CC genotypes) does not have a significant association with the incidence or presence of CMV infection in kidney transplant patients.
- 30 November 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 14, e38389
Open AccessThe aquaporin 5 promoter polymorphism and cytomegalovirus infection in kidney transplant recipients
Introduction: Cytomegalovirus (CMV) infection is a significant complication in kidney transplant recipients, impacting graft function and overall patient outcomes. Aquaporin 5 (AQP5) is a transmembrane channel that regulates renal function and impacts important mechanisms of immune cell migration and inflammation. Objectives: This research aimed to evaluate the impact of AQP5 polymorphism (-1364A/C) on the risk of CMV infection in kidney transplant recipients. Patients and Methods: One-hundred kidney transplant recipients were included in this study, divided into two groups; CMV+-positive (n=50) and CMV– -negative (n=50) patients. Additionally, a control group of 50 healthy individuals was included. The frequency of the AQP5 (-1364A/C) gene polymorphism was determined using the ARMS-PCR technique. Results: About 26% and 16% of patients in the CMV+ and CMV- groups experienced acute rejection after renal transplantation, respectively (P=0.220). The CC genotype of AQP5 (-1364A/C) polymorphism was present in 8% (n=4) of CMV+ and 4% (n=2) of CMV- recipients (4%); however, it was not observed in the control group (P=0.354). Conclusion: The results revealed that carrying at least one C-allele of the AQP5 1364A/C polymorphism (AC or CC genotypes) does not have a significant association with the incidence or presence of CMV infection in kidney transplant patients.
- 9 October 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 101
The potential of metformin nanoformulations for cancer prevention and therapy
- 9 October 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 101
The potential of metformin nanoformulations for cancer prevention and therapy
- Open Access
- 2 July 2024
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (4) , e1228
Effectiveness of edaravone in preventing contrast‐induced nephropathy in high‐risk patients undergoing coronary angiography: A randomized, double‐blind trial
Contrast‐induced nephropathy (CIN) is a serious complication that occurs subsequent to the administration of contrast media for therapeutic angiographic interventions. As of present, no effective therapy exists to prevent its occurrence. This single‐center double‐blind randomized controlled trial aimed to evaluate the effect of edaravone, an antioxidant, in a group of high‐risk patients undergoing coronary angiography. Ninety eligible patients with chronic kidney disease Stages 3–4 were randomly assigned to either the control group (n = 45) or the intervention group (n = 45). In the intervention group, one dosage of edaravone (60 mg) in 1 L of normal saline was infused via a peripheral vein 1 h prior to femoral artery‐directed coronary angiography. Patients in the control group received an equal amount of infusion in their last hour before angiography. Both groups received intravenous hydration with 0.9% sodium 1 mL/kg/h starting 12 h before and continuing for 24 h after angiography. The primary outcome measure was the onset of CIN, defined as a 25% increase in serum creatinine levels 120 h after administration of contrast media. The occurrence of CIN was observed in 5.5% (n = 5) of the studied population: 2.2% of patients in the intervention group (n = 1) and 8.9% of controls (n = 4). However, this difference was not statistically significant. Administration of a single dosage of edaravone 1 h prior to infusion of contrast media led to a reduction in the incidence of CIN. Further investigations, employing larger sample sizes, are warranted to gain a comprehensive understanding of its efficacy.
- 2 July 2024
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (4) , e1228
Open AccessEffectiveness of edaravone in preventing contrast‐induced nephropathy in high‐risk patients undergoing coronary angiography: A randomized, double‐blind trial
Contrast‐induced nephropathy (CIN) is a serious complication that occurs subsequent to the administration of contrast media for therapeutic angiographic interventions. As of present, no effective therapy exists to prevent its occurrence. This single‐center double‐blind randomized controlled trial aimed to evaluate the effect of edaravone, an antioxidant, in a group of high‐risk patients undergoing coronary angiography. Ninety eligible patients with chronic kidney disease Stages 3–4 were randomly assigned to either the control group (n = 45) or the intervention group (n = 45). In the intervention group, one dosage of edaravone (60 mg) in 1 L of normal saline was infused via a peripheral vein 1 h prior to femoral artery‐directed coronary angiography. Patients in the control group received an equal amount of infusion in their last hour before angiography. Both groups received intravenous hydration with 0.9% sodium 1 mL/kg/h starting 12 h before and continuing for 24 h after angiography. The primary outcome measure was the onset of CIN, defined as a 25% increase in serum creatinine levels 120 h after administration of contrast media. The occurrence of CIN was observed in 5.5% (n = 5) of the studied population: 2.2% of patients in the intervention group (n = 1) and 8.9% of controls (n = 4). However, this difference was not statistically significant. Administration of a single dosage of edaravone 1 h prior to infusion of contrast media led to a reduction in the incidence of CIN. Further investigations, employing larger sample sizes, are warranted to gain a comprehensive understanding of its efficacy.
- Open Access
- 19 May 2024
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 46 (3) , 248-255
Effects of fingolimod on heart injury induced by renal ischemia-reperfusion
Background. Renal ischemia-reperfusion injury (IRI) is one of the inevitable complications of surgery. The evidence shows that fingolimod, with its anti-inflammatory effects, can play a protective role in renal IRI. The main aim of the present study was to investigate the role of fingolimod against renal IRI in the heart tissue. Methods. Twenty-four male Wistar rats (220±20g) were treated with a single dose of fingolimod (1mg/kg) by intraperitoneal injection before the induction of kidney IRI. At the end of the reperfusion period, the oxidative stress biomarker (malondialdehyde) and antioxidant biomarkers (catalase, superoxide dismutase, glutathione, glutathione peroxidase, and total antioxidant capacity) were evaluated in the heart tissue. Results. Fingolimod pretreatment could increase cardiac glutathione enzyme activity in the fingolimod+IR group compared to the IR group, which was not statistically significant (P>0.05). The level of total antioxidant capacity in the heart tissue was also significantly increased in the fingolimod+IR group in comparison to the IR group (P<0.05). Conclusion. Fingolimod was able to prevent oxidative stress damage in the heart caused by kidney IR induction by increasing the level of total antioxidant capacity of the heart tissue. It is suggested that future studies evaluate the effects of this drug in clinical trials. Practical Implications. The total antioxidant capacity of the heart, as a distant organ affected by kidney IRI, is increased following fingolimod pre-treatment.
- 19 May 2024
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 46 (3) , 248-255
Open AccessEffects of fingolimod on heart injury induced by renal ischemia-reperfusion
Background. Renal ischemia-reperfusion injury (IRI) is one of the inevitable complications of surgery. The evidence shows that fingolimod, with its anti-inflammatory effects, can play a protective role in renal IRI. The main aim of the present study was to investigate the role of fingolimod against renal IRI in the heart tissue. Methods. Twenty-four male Wistar rats (220±20g) were treated with a single dose of fingolimod (1mg/kg) by intraperitoneal injection before the induction of kidney IRI. At the end of the reperfusion period, the oxidative stress biomarker (malondialdehyde) and antioxidant biomarkers (catalase, superoxide dismutase, glutathione, glutathione peroxidase, and total antioxidant capacity) were evaluated in the heart tissue. Results. Fingolimod pretreatment could increase cardiac glutathione enzyme activity in the fingolimod+IR group compared to the IR group, which was not statistically significant (P>0.05). The level of total antioxidant capacity in the heart tissue was also significantly increased in the fingolimod+IR group in comparison to the IR group (P<0.05). Conclusion. Fingolimod was able to prevent oxidative stress damage in the heart caused by kidney IR induction by increasing the level of total antioxidant capacity of the heart tissue. It is suggested that future studies evaluate the effects of this drug in clinical trials. Practical Implications. The total antioxidant capacity of the heart, as a distant organ affected by kidney IRI, is increased following fingolimod pre-treatment.
- Open Access
- 5 August 2023
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Effect of pioglitazone on proteinuria and cardiovascular events in patients with diabetic nephropathy
Introduction: Slowing the progression of diabetes to DN has established a great deal of interest in recent years. Objectives: Considering the enormous costs of managing patients with diabetes and the lack of similar studies on the Iranian population, the present study aimed at investigating the effect of pioglitazone on the progression of DN and the prevalence of cardiovascular events. Patients and Methods: The present prospective study was undertaken on 55 patients with type 2 diabetes who were divided into two groups. The group 1 patients received 30 mg of pioglitazone daily in addition to other blood sugar-controlling drugs. Patients in the group 2 recieved other anti-diabetic medications. During a six-month follow-up period, proteinuria and the occurrence of cardiovascular events were assessed. Results: The 24-hour urinary proteinuria decreased within the group 1 and these intragroup differences were significant (P<0.001) during six months of follow-up compared to month two. There was no significant difference in the ratio of cardiovascular events in the group 1 compared to the group 2. Conclusion: Adding 30 mg of pioglitazone to other blood sugar-lowering medications could lower proteinuria in individuals with type 2 diabetes; however, it had no impact on the risk of cardiovascular events.
- 5 August 2023
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Open AccessEffect of pioglitazone on proteinuria and cardiovascular events in patients with diabetic nephropathy
Introduction: Slowing the progression of diabetes to DN has established a great deal of interest in recent years. Objectives: Considering the enormous costs of managing patients with diabetes and the lack of similar studies on the Iranian population, the present study aimed at investigating the effect of pioglitazone on the progression of DN and the prevalence of cardiovascular events. Patients and Methods: The present prospective study was undertaken on 55 patients with type 2 diabetes who were divided into two groups. The group 1 patients received 30 mg of pioglitazone daily in addition to other blood sugar-controlling drugs. Patients in the group 2 recieved other anti-diabetic medications. During a six-month follow-up period, proteinuria and the occurrence of cardiovascular events were assessed. Results: The 24-hour urinary proteinuria decreased within the group 1 and these intragroup differences were significant (P<0.001) during six months of follow-up compared to month two. There was no significant difference in the ratio of cardiovascular events in the group 1 compared to the group 2. Conclusion: Adding 30 mg of pioglitazone to other blood sugar-lowering medications could lower proteinuria in individuals with type 2 diabetes; however, it had no impact on the risk of cardiovascular events.
- Open Access
- 19 December 2022
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 44 (5) , 403-415
Injection of intravenous immunoglobulin (IVIg) for the treatment of Coronavirus induced cytokine storm
Background. COVID-19 disease is the cause of daily morbidity and mortality worldwide due to its high transmissibility and pathogenicity. To date, intravenous immunoglobulin (IVIg) injection has been used as one of the various treatments for this disease. This study aimed to determine the effect of IVIg injection on the treatment of patients with Coronavirus-induced cytokine storm. Methods. A total of 174 patients with COVID-19 were included in this study based on their clinical characteristics and laboratory findings and were divided into two groups of IVIg recipients and non-recipients according to the treatment they received. Statistical analysis was performed using SPSS version 22.0. A p-value less than 0.05 was considered statistically significant. Results. IVIg was used to treat merely 20 patients and Kaletra and hemoperfusion drugs were used more among IVIg recipient patients (P=0.003 and P=0.001, respectively). COVID-19-positive PCR tests were significantly more frequent among IVIg recipients (P=0.026). The polymorphonuclear neutrophil (PMN) count (P=0.007) and sodium level (P=0.007) were significantly higher in the IVIg recipient group on the first admission day. Moreover, INR levels in the IVIg recipient group were significantly lower on the seventh admission day (P=0.020). The median of total intensive care unit (ICU) duration of hospitalization among IVIg recipients was significantly higher (P=0.001). Conclusion. It seems that the use of IVIg in COVID-19 patients should be further investigated. Practical Implications. IVIg injection could decrease mortality and slightly increase the survival rate among COVID-19 patients.
- 19 December 2022
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 44 (5) , 403-415
Open AccessInjection of intravenous immunoglobulin (IVIg) for the treatment of Coronavirus induced cytokine storm
Background. COVID-19 disease is the cause of daily morbidity and mortality worldwide due to its high transmissibility and pathogenicity. To date, intravenous immunoglobulin (IVIg) injection has been used as one of the various treatments for this disease. This study aimed to determine the effect of IVIg injection on the treatment of patients with Coronavirus-induced cytokine storm. Methods. A total of 174 patients with COVID-19 were included in this study based on their clinical characteristics and laboratory findings and were divided into two groups of IVIg recipients and non-recipients according to the treatment they received. Statistical analysis was performed using SPSS version 22.0. A p-value less than 0.05 was considered statistically significant. Results. IVIg was used to treat merely 20 patients and Kaletra and hemoperfusion drugs were used more among IVIg recipient patients (P=0.003 and P=0.001, respectively). COVID-19-positive PCR tests were significantly more frequent among IVIg recipients (P=0.026). The polymorphonuclear neutrophil (PMN) count (P=0.007) and sodium level (P=0.007) were significantly higher in the IVIg recipient group on the first admission day. Moreover, INR levels in the IVIg recipient group were significantly lower on the seventh admission day (P=0.020). The median of total intensive care unit (ICU) duration of hospitalization among IVIg recipients was significantly higher (P=0.001). Conclusion. It seems that the use of IVIg in COVID-19 patients should be further investigated. Practical Implications. IVIg injection could decrease mortality and slightly increase the survival rate among COVID-19 patients.